Literature DB >> 23222677

Impact of OKT3 Therapy on Cytomegalovirus and Herpes Simplex Virus Infections After Liver Transplantation.

N Singh1, J S Dummer, S Kusne, L Makowka, T E Starzl, M Ho.   

Abstract

Entities:  

Year:  1988        PMID： 23222677      PMCID： PMC3034373     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  2 in total

1.  Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.

Authors:  M J Bia; W Andiman; K Gaudio; A Kliger; N Siegel; D Smith; W Flye
Journal:  Transplantation       Date:  1985-12       Impact factor: 4.939

2.  Viral infections in renal transplant recipients.

Authors:  J A Armstrong; A S Evans; N Rao; M Ho
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441
  2 in total
  4 in total

1.  Infections with FK 506 immunosuppression: preliminary results with primary therapy.

Authors:  M Alessiani; S Kusne; F M Martin; J J Fung; A Jain; S Todo; R Simmons; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

Review 2.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

3.  Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.

Authors:  M Sakr; T Hassanein; J Gavaler; K Abu-Elmagd; J Fung; R Gordon; T Starzl; D Van Thiel
Journal:  Transplantation       Date:  1992-04       Impact factor: 4.939

Review 4.  Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis: Case report and review of the literature.

Authors:  Varun K Phadke; Rachel J Friedman-Moraco; Brian C Quigley; Alton B Farris; J P Norvell
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.